GENENTECH, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
Study to Investigate the Effect of Formulation and Food on the Pharmacokinetics of GDC-0810
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2016-03-29
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT02722018
- Locations
- 🇬🇧
Quotient Clinical Ltd, Clinical Research Unit, Nottingham, United Kingdom
Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2016-03-04
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT02699710
- Locations
- 🇬🇧
Quotient Clinical Ltd, Clinical Research Unit, Nottingham, United Kingdom
A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)
- First Posted Date
- 2016-03-03
- Last Posted Date
- 2017-09-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT02698566
- Locations
- 🇺🇸
Southeastern Retina Associates, Chattanooga, Tennessee, United States
🇺🇸Char Eye Ear &Throat Assoc, Charlotte, North Carolina, United States
🇺🇸Paducah Retinal Center, Paducah, Kentucky, United States
Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)
- Conditions
- Multiple Sclerosis, Primary ProgressiveRelapsing Multiple Sclerorsis
- Interventions
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 131
- Registration Number
- NCT02688985
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸University of Massachusetts Medical School, Worcester, Massachusetts, United States
A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- First Posted Date
- 2016-01-14
- Last Posted Date
- 2020-08-06
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT02655614
- Locations
- 🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸Mayo Clinic Hospital - Florida, Jacksonville, Florida, United States
🇺🇸Forbes Norris Mda/als Ctr; Research Center, San Francisco, California, United States
Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
- First Posted Date
- 2015-12-28
- Last Posted Date
- 2019-12-23
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT02640092
- Locations
- 🇺🇸
Molecular NeuroImaging, New Haven, Connecticut, United States
🇺🇸Bio Behavioral Health, Toms River, New Jersey, United States
🇺🇸NeuroCognitive Institute, Mount Arlington, New Jersey, United States
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
- First Posted Date
- 2015-12-22
- Last Posted Date
- 2020-05-26
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 608
- Registration Number
- NCT02637856
- Locations
- 🇺🇸
The Ohio State University Wexner Medical Center; Department of Neurology, Columbus, Ohio, United States
🇺🇸Allegheny Neurological Associates, Pittsburgh, Pennsylvania, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Study to Evaluate Pain, Tolerability, Safety, and Usability of a Single Self-administered Etrolizumab by Auto-injector in Healthy Participants
- Conditions
- Healthy Volunteer
- Interventions
- Device: Prefilled Auto-injector (Rotaject)
- First Posted Date
- 2015-12-14
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT02629744
A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults
- First Posted Date
- 2015-12-07
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT02623322
- Locations
- 🇺🇸
Oceane7 Clinical Research, Miami, Florida, United States
🇺🇸North Alabama Research Center LLC, Athens, Alabama, United States
🇺🇸Lalla-Reddy Medical Corporation, Fountain Valley, California, United States
Effect of GDC-0810 on the Pharmacokinetics of Pravastatin in Healthy Female Subjects of Non-Childbearing Potential
- First Posted Date
- 2015-12-04
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT02621957